Japan

Taisho Pharmaceutical

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

JAPAN Japan

Post An Enquiry

Virtual Booth

PHARMACEUTICAL MARKETING

Participation Not Confirmed

Update your events

Chugai Pharma, Taisho Pharma Terminate Co-Marketing Agreement for Edirol to Treat Osteoporosis

Lead Product(s): Eldecalcitol

Therapeutic Area: Musculoskeletal Product Name: Edirol

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Chugai Pharmaceutical

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Termination January 22, 2021

Details:

Chugai Pharmaceutical and Taisho Pharmaceutical announced termination of the agreement between both companies regarding co-marketing of Edirol® Capsules 0.5 µg and 0.75 µg, a treatment for osteoporosis for which Chugai has a marketing authorization.

Chugai Pharmaceutical

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

JAPAN Japan

Post An Enquiry

Virtual Booth

PHARMACEUTICAL MARKETING

Participation Not Confirmed

Update your events

Chugai's Osteoporosis Agent Edirol Obtains Regulatory Approval in China

Lead Product(s): Eldecalcitol

Therapeutic Area: Musculoskeletal Product Name: Edirol

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable December 18, 2020

Details:

Chugai has obtained regulatory approval for eldecalcitol (product name: Edirol®), an active vitamin D3 derivative created by Chugai from the China National Medical Products Administration (NMPA).